Generation of recombinant vaccinia viruses

Current Protocols in Molecular Biology

Volumn 2017, Issue , 2017, Pages

  Wyatt, Linda S ^a   Earl, Patricia L ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID VECTOR;

ANIMAL CELL; ARTICLE; CELLS; DNA SEQUENCE; GENE AMPLIFICATION; GENE INSERTION; GENETIC TRANSFECTION; HOMOLOGOUS RECOMBINATION; IMMUNOHISTOCHEMISTRY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING; VACCINIA VIRUS; VIRUS DETECTION; VIRUS INFECTION; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; CELL LINE; GENE VECTOR; GENETICS; HUMAN; PLASMID; PROCEDURES;

ANIMALS; CELL LINE; GENETIC VECTORS; HOMOLOGOUS RECOMBINATION; HUMANS; IMMUNOHISTOCHEMISTRY; PLASMIDS; POLYMERASE CHAIN REACTION; TRANSFECTION; VACCINIA VIRUS;

EID: 85025432190     PISSN: 19343639     EISSN: 19343647     Source Type: Journal    
DOI: 10.1002/cpmb.32     Document Type: Article

References (39)

1. Bacik, I., Cox, J.H., Anderson, R., Yewdell, J.W., and Bennink, J.R. 1994. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino-but not carboxyl-terminus of the peptide. J. Immunol. 152:381-387.
2. Bertholet, C., Drillien, R., and Wittek, R. 1985. One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc. Natl. Acad. Sci. U.S.A. 82:2096-2100. doi: 10.1073/pnas.82.7.2096.
3. Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P.L., Murphy, B.R., Subbarao, K., and Moss, B. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U.S.A. 101:6641-6646. doi: 10.1073/pnas.0401939101.
4. Blasco, R. and Moss, B. 1995. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157-162. doi: 10.1016/0378-1119(95)00149-Z.
5. Burrill, C.P., Strings, V.R., Schulte, M.B., and Andino, R. 2013. Poliovirus: Generation and characterization of mutants. Curr. Protoc. Microbiol. 29:15H.2.1-15H.2.32.
6. Carroll, M.W. and Moss, B. 1995. E. coli ß-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. BioTechniques 19:352-355.
7. Carroll, M.W. and Moss, B. 1997. Host range and cytopathogenicity of the highly attenuatedMVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238:198-211. doi: 10.1006/viro.1997.8845.
8. Chakrabarti, S., Brechling, K., and Moss, B. 1985. Vaccinia virus expression vector: Coexpression of beta-galatosidase provides visual screening of recombinant virus plaques. Mol. Cell Biol. 5:3403-3409.
9. Chakrabarti, S., Sisler, J.R., and Moss, B. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 23:1094-1097.
10. Cochran, M.A., Puckett, C., and Moss, B. 1985. In vitro mutagenesis of the promoter region for a vaccinia virus gene: Evidence for tandem early and late regulatory signals. J. Virol. 54:30-37.
11. Cotter, C.A., Earl, P.L., Wyatt, L.S., and Moss, B. 2017. Preparation of cell cultures and vaccinia virus stocks. Curr. Protoc. Mol. Biol. 117:16.16.1-16.16.18. doi: 10.1002/cpmb.33
12. Davison, A.J. and Moss, B. 1990. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res. 18:4285-4286. doi: 10.1093/nar/18.14.4285.
13. Domi, A. and Moss, B. 2005. Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambdabased recombination. Nat. Methods 2:95-97. doi: 10.1038/nmeth734.
14. Earl, P., Koenig, S., and Moss, B. 1990. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: Analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31-41.
15. Elroy-Stein, O. and Moss, B. 2001. Gene expression using the vaccinia virus/T7RNApolymerase hybrid system. Curr. Protoc. Mol. Biol. 43:16.19.1-16.19.11.
16. Falkner, F.G. and Moss, B. 1988. Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J. Virol. 62:1849-1854.
17. Falkner, F.G. and Moss, B. 1990. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 64:3108-3111.
18. Heilig, J., Elbing, K.L., and Brent, R. 1998. Largescale preparation of plasmidDNA. Curr. Protoc. Mol. Biol. 41:1.7.1-1.7.16.
19. Isaacs, S.N., Kotwal, G.J., and Moss, B. 1990. Reverse guanine phosphoribosyltransferase selection of recombinant vaccinia viruses. Virology 178:626-630. doi: 10.1016/0042-6822(90)90367-Z.
20. Kingston, R.E., Chen, C.A., and Rose, J.K. 2003. Calcium phosphate transfection. Curr. Protoc. Mol. Biol. 63:9.1.1-9.1.11.
21. Kramer, M. F. and Coen, D. M. 2000. Enzymatic amplification of DNA by PCR: Standard procedures and optimization. Curr. Protoc. Mol. Biol. 56:15.1.1-15.1.14.
22. Mackett, M., Smith, G.L., andMoss, B. 1984. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49:857-864.
23. Merchlinsky, M., Eckert, D., Smith, E., and Zauderer, M. 1997. Construction and characterization of vaccinia direct ligation vectors. Virology 238:444-451. doi: 10.1006/viro.1997.8828.
24. Meyer, H., Sutter, G., and Mayr, A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038. doi: 10.1099/0022-1317-72-5-1031.
25. Mortensen, R.M. and Kingston, R.E. 2009. Selection of transfected mammalian cells. Curr. Protoc. Mol. Biol. 86: 9.5.1-9.5.13.
26. Moss, B. and Earl, P.L. 2002. Overview of the vaccinia virus expression system. Curr. Protoc. Mol. Biol. 60:16.15.1-16.15.5.
27. Ourmanov, I., Brown, C.R., Moss, B., Carroll, M., Wyatt, L., Pleteva, L., Goldstein, S., Venson, D., and Hirsch, V.M. 2000. Comparative efficacy of recombinant modified vaccinia virus ankara expressing simian immunodeficiency virus (SIV) gag-pol and/or env in macaque challenged with pathogenic SIV. J. Virol. 74:2740-2751. doi: 10.1128/JVI.74.6.2740-2751.2000.
28. Patel, D.D., Ray, C.A., Drucker, R.P., and Pickup, D.J. 1988. A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 85:9431-9435. doi: 10.1073/pnas.85.24.9431.
29. Pfleiderer, M., Falkner, F.G., and Dorner, F. 1995. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts. J. Gen. Virol. 76:2957-2962. doi: 10.1099/0022-1317-76-12-2957.
30. Phelan, M.C. 2006. Techniques for mammalian cell tissue culture. Curr. Protoc. Mol. Biol. 4:F:A.3F.1-A.3F.18.
31. Scheiflinger, F., Falkner, F.G., and Dorner, F. 1996. Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vacciniaMVA strain. Arch. Virol. 141:663-669. doi: 10.1007/BF01718324.
32. Shendure, J.A., Porreca, G.J., Church, G.M., Gardner, A.F., Hendrickson, C.L., Kieleczawa, J., and Slatko, B.E. 2011. Overview of DNA sequencing strategies. Curr. Protoc. Mol. Biol. 96:7.1.1-7.1.23.
33. Smith, G.L. and Moss, B. 1983. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25:21-28. doi: 10.1016/0378-1119(83)90163-4.
34. Struhl, K. 1987. Subcloning of DNA fragments. Curr. Protoc. Mol. Biol. 13:3.16.1-3.16.2.
35. Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R., and Moss, B. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040. doi: 10.1016/0264-410X(94)90341-7.
36. Voytas, D. 2000. Agarose gel electrophoresis. Curr. Protoc. Mol. Biol. 51:2.5A.1-2.5A.9.
37. Wyatt, L.S., Shors, S.T., Murphy, B.R., and Moss, B. 1996. Development of a replicationdeficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451-1458. doi: 10.1016/S0264-410X(96)00072-2
38. Wyatt, L.S., Earl, P.L., Xiao, W., Americo, J.A., Cotter, C.A., Vogt, J., and Moss, B. 2009. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J. Virol. 83:7176-7184. doi: 10.1128/JVI.00687-09.
39. Wyatt, L.S., Earl, P.L., Vogt, J., Eller, L.A., Chandran, D., Liu, J., Robinson, H.L., and Moss, B. 2008. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26:486-493. doi: 10.1016/j.vaccine.2007.11.036.